- Windaus A. Über den Gehalt normaler und atheromatöser Aorten an Cholesterin und Holesterinestern. Hoppe Seylers Z Physiol Chem 1910, 67:174-176.
- Anitchkow NN, Chalatov S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. ZbI allg Path Anat 1913; 24:1-9.
- Constantinides P. Experimental Atherosclerosis. Amsterdam: Eisevier, 1965.
- Sinitzina TA. Experimental Atherosclerosis of Heart Coronary Arteries. Leningrad: Meditzina, 1964 (in Russian).
- KlimovAN, Petrova-Maslakova LG, Rodionova LP, Sinitzina TA. Atherosclerosis induced experimentally by repeated intravenous administration of hypercholesterolemic serum and of lipoproteine. In Di Luzio NR, Paoletti R, eds. Reticuloendothelial System and Atherosclerosis. New York: Plenum Press, 1967; 442-450.
- Taylor CB, Peng SK, Werthessen NT, Tham P, Lee KT. Spontaneously occurring angiotoxic derivatives of cholesterol. Am J Clin Nutr 1979;32:40-57.
- Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999;142:1-28.
- Dayton S, Hashimoto S. Recent advances in molecular pathology: a review. Cholesterol flux and metabolism in arterial tissue and in atheroma. Exp Mol Pathol 1970;13:253-268.
- Klimov AN, Nagornev VA. Mechanisms of lipoprotein penetration into the arterial wall leading to development of atherosclerosis. Athero Rev 1983;11:107-156.
- Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHLrabbit): incidence and development of atherosclerosis and xantoma. Atherosclerosis 1980,36:261-268.
- Law MR, WaId NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemie heart disease? Br Med J 1994;308: 367-372.
- Haust D. The morphogenesis and fate of potential and early atherosclerotic lesions in man. Hum Pathol 1971; 2:1-29.
- Haust D, Balis J, More R. Electron microscopic study of intimai lipid accumulations in human aorta and their pathogenesis. Circulation 1962;26:656-671.
- Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983;52:223-261.
- Klimov AN, Denisenko AD, Popov AV, et al. Lipoprotein-antibody immune complexes: their catabolism and role in foam cell formation. Atherosclerosis 1985;58:1-15.
- Kruth HS. The fate of lipoprotein cholesterol entering the arterial wall. Curr Opin Lipidol 1997;8:246-252.
- Yin J, Chaufour X, McLachlan C, et al. Apoptosis of vascular smooth muscle cells induced by cholesterol and its oxides in vitro and in vivo. Atherosclerosis 2000;148:365-374.
- Aupeix K, Weltin D, Mejia JE, et al. Oxysterol-induced apoptosis in human monocytic cell lines. Immunobiology 1995;194:415-428.
- Lizard G, Deckert V, Dubretz L, Moisant M, Gambert P, Lagrost L. Induction of apoptosis in endothelial cells treated with cholesterol oxides. Am J Pathol 1996;148: 1625-1638.
- Anitchkov NN. New data on pathology and etiology of atherosclerosis. Russian Physician 1915;8:184-186 (in Russian).
- Earth JD, Hodis HN. The atherosclerosis regression trials-is it all good news? In Betteridge DJ, ed. Lipids: Current Perspectives, vol. 3 Management. London: Martin Dunitz, 1996;245-257.
- Betteridge DJ. Cholesterol lowering and secondary prevention of CHD--the evidence of benefit is unequivocal. In Betteridge DJ, ed. Lipids: Current Perspectives, vol. 3. Management. London: Martin Dunitz, 1996; 261-271.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
- West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
- Sacks FM, Pfeffer MA, Moyle LA, et al. The effect of pravastati n on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1998,335:1001-1009.
- The Long-term Intervention with Pravastati n in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastati n in patients with coronary heart disease and a broad range of initial cholesterol levels. N EnglJ Med 1998;339:1349-1358.
- Davignon J. The pleiotropic effects of drugs affecting lipid metabolism. In Jacotot B, Mathe D, Fruchart J-C, eds. Atherosclerosis XI. Singapore: Elsevier Science, 1998:63-77.
- Anitchkov NN. On experimental atherosclerosis. Arch Biol Sci 1932;32:4-20 (in Russian).
- Zinserling VD. Morphology of human atherosclerosis. Clin Med 1937;15:521-527 (in Russian).
- Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938;suppl. 89:75-84.
- Goodman DS, Deykin D, Shiratori T. The formation of cholesterol esters with rat liver enzymes. J Biol Chem 1964;239:1335-1345.
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins -- an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-42, 94-103, 148-156, 215-225, and 273-281.
- Glomset J. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
- Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet 1975;1:16-19.
- Steinberg D. Metabolism of lipoproteins and their role in the pathogenesis of atherosclerosis. Athero Rev 1988;18:l-23.
- Vercellotti G. Infectious agents that play a role in atherosclerosi s and vasculopathies. What are they? What do we do about them? Can J Cardiol 1999;15 (suppl B):13B-15B.
- Benditt EP, Benditt JM. Evidence for monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973;70:1753-1756.
Pediatric Pathology & Molecular Medicine
Volume 21, 2002 - Issue 3